Document:

<PAGE>

                                                                   EXHIBIT 10.18

                                    AGREEMENT
                    ON MANUFACTURING, SALES AND DISTRIBUTION
                            LICENSE FOR HMRLIGNAN(TM)
                         made this 8th day of April 2005
                  (hereinafter referred to as the "Agreement")

                                 By and between

                             LINNEA S.A. ("LINNEA")
                     Via Cantonale, 6595 Riazzino (Locarno)
                                   Switzerland

                                       and

                      HORMOS MEDICAL CORPORATION ("HORMOS")
                            Company ID: FI 1085385-9
                               Itainen Pitkakatu 4
                            FIN-20520 Turku, Finland

                  LINNEA and HORMOS are hereinafter referred to
             individually as a "Party" or collectively as "Parties"

Whereas,        HORMOS has proprietary rights, experience and expertise related
                to research and development of compounds extracted from nature
                for nutraceutical use, especially a lignan called
                ********** (HMR). Furthermore, HORMOS has submitted a
                notification with the US Food and Drug Administration to market
                HMR as a new dietary ingredient.

Whereas,        LINNEA has special experience and expertise on development,
                extraction, production and commercialisation of natural
                compounds for dietary and nutraceutical use.

Whereas,        The Parties are willing to cooperate to further commercialise
                HMRlignan(TM).

                                      - 1 -
<PAGE>

      NOW, therefore the Parties have agreed as follows:

1.    DEFINITIONS

      For the purpose of this Agreement:

      "Affiliates" shall mean:

            a)    any organisation or business entity of which fifty percent
                  (50%) or more of the voting stock is controlled or owned
                  directly or indirectly by a Party;

            b)    any organisation or business entity which directly or
                  indirectly owns or controls fifty percent (50%) or more of the
                  voting stock of the Party;

            c)    any organisation or business entity, the majority ownership of
                  which is directly or indirectly common to, or commonly owned
                  or controlled by the majority ownership of the Party.

      "Bulk Market Price" shall mean fair market price for HMR Bulk Ingredient
            sold at the time in the same or comparable market, if available.

      "Confidential Information" shall mean information in any tangible form,
            data and experience clearly identified as confidential, not
            available to the general public, and disclosed to the other Party,
            whether (by way of example) scientific, technical, engineering,
            operational or economic by nature.

      "Dietary Supplement Product(s)" shall mean any dietary ingredient product,
            as defined in the US "Dietary Supplement and Health Education Act,
            in any galenic formulation intended for consumer use which do not
            require GRAS, Novel Food or Pharmaceutical regulatory clearance,
            containing HMR Bulk Ingredient. "Functional Food" shall mean food
            products containing HMR Bulk Ingredient intended for consumer use
            and require GRAS and/or Novel Food approval in order to be marketed.

      "GRAS" shall mean "Generally Recognized As Safe" regulatory clearance by
            US Food and Drug Administration.

      "HMRlignan(TM)" shall mean HORMOS' ******** (HMR, *****)
            platform consisting of the Patents, technology, Know-How and
            documentation related to said concept;

      "HMR Bulk Ingredient" shall mean the bulk ingredient containing HMR as
            its sole active ingredient which development, manufacture and/or
            commercialisation would infringe Hormos' Patents and Know-How
            regarding the bulk ingredient should this Agreement be absent.

      "Know-How" shall mean information, results and documentation related to
            HMRlignan(TM) and owned or controlled by Hormos. Know-How is
            exclusively detailed in section 5.3.

      "Material Breach" shall mean a breach of any of the sections 6.1, 6.2,
            6.4, 7, 7.1, 7.1.1, 7.1.2, 8, 9.1 or 9.2 provided that such breach
            is related to material obligations set forth in said section and
            causing damages or loss to the other Party or having a negative
            effect on the position of the other Party.

      "Net Sales" shall mean gross amount invoiced by LINNEA or its Affiliates
            on account of sales of HMR Bulk Ingredients to customers, less the
            following deductions to the extent

                                      - 2 -
<PAGE>

            actually allowed or specifically allocated to HMR Bulk Ingredient
            using generally accepted accounting standards:

            (i)   value added taxes, sales and excise taxes and duties paid or
                  allowed by the selling party and any other governmental
                  charges imposed upon the importation or sale of HMR Bulk
                  Ingredient;

            (ii)  customary and reasonable trade, quantity and cash discounts
                  actually allowed with respect to the sale HMR Bulk Ingredient;

            (iii) customary and reasonable allowances or credits to customers on
                  account of rejection, withdrawal, recall or return of sold
                  goods;

            (iv)  customary and reasonable freight and insurance costs, if they
                  are included in the selling price invoiced to customers or
                  otherwise paid by customers, provided always that such
                  deduction shall not be greater than the balance between the
                  selling price actually invoiced to the customer and the
                  standard selling price which would have been charged to such
                  customer for such Products exclusive of freight and insurance
                  costs

      "Novel Food" shall mean the criteria stated in the European Union
            regulatory authority regulation 257/97.

      "Patent(s)" shall mean any patent or patent application granted or pending
            in any country of the world relevant or necessary for manufacturing,
            developing and/or marketing of HMRlignan(TM), and owned or
            controlled at the Date of the Agreement or in the future by Hormos,
            including those detailed in Section 5 and Schedule 1 attached
            hereto, and including all reissues, extensions, substitutions,
            confirmations, registrations, revalidations, additions,
            continuations in part, refilings and divisions thereof and any
            supplemental protection certificates;

      "Patent Protection Territory" shall mean any country in the world where a
            patent based on the US patent ***** "**************************
            ******************************************************************
            ********************************************************************
            ********************************************************
            (application No. US *********) is granted or pending at the Date of
            the Agreement.

      "Prescription Pharmaceutical Product" shall mean any pharmaceutical
            product with regulatory approval for any indication and in any
            galenic formulation that requires doctor's prescription in order to
            be sold to the consumers according to the national laws. For
            avoidance of doubt, OTC products are not Prescription Pharmaceutical
            Products.

      "Scope of the Agreement" shall mean HORMOS' rights to be licensed or
            materials to be transferred, as the case may be, related to
            HMRlignan(TM) as defined in this Agreement but consisting
            exhaustively of

            1.    Patents as described in section 5.1.

            2.    Know-how & Documentation as described in section 5.2.

            3.    Trademarks as described in section 5.3

            4.    Regulatory notifications as described in section 5.4

            5.    Raw Material as described in section 5.5.

      "Term" shall mean the period of time commencing on the Date of the
            Agreement and ending at the expiry of US patent ****** including
            any extension possibly granted to it.

                                      - 3 -
<PAGE>

      "Trademarks" shall mean Hormos proprietary trademarks set forth Section 5
      and in Schedule 1;

2.    GRANT OF LICENSE

2.1.  HORMOS hereby grants LINNEA for the Patents, Trademarks and Know-How &
      Documentation an exclusive world-wide license right to develop,
      manufacture, market and distribute HMR Bulk Ingredient for the purpose of
      developing, manufacturing, selling and marketing Dietary Supplement
      Products, including the right to grant sublicenses to third parties to
      develop, manufacture, sell and market Dietary Supplement Products, subject
      to the terms and conditions of this Agreement. HORMOS shall not grant the
      same right to any third party nor exercise the rights itself save for that
      HORMOS shall retain the nonexclusive right to market HMRlignan(TM) in
      finished forms as further defined in in sections 2.3 and 3.3 of this
      Agreement.

2.2.  Exclusion of granted licenses. For avoidance of doubt, nothing in this
      agreement shall be construed as a grant of license by HORMOS to LINNEA

      (i)   to develop, manufacture, market and distribute HMRlignan(TM) in
            Functional Foods for any purpose or indication,

      (ii)  to develop, manufacture, market and distribute HMRlignan(TM) in
            applications where GRAS and/or Novel Food regulatory clearance is a
            prerequisite for a marketing license

      (iii) to market or sell bulk ingredient containing HMRlignan(TM) for
            Prescription Pharma formulation, unless otherwise agreed in this
            Agreement.

2.3.  Non-exclusive rights retained by HORMOS. HORMOS shall retain the right to
      manufacture or have manufactured the products containing HMRlignan(TM),
      develop, import, market and distribute Dietary Supplement Products in the
      USA. When producing such Dietary Supplement Products for the US market,
      Hormos shall purchase HMR Bulk Ingredient from LINNEA under reasonable
      commercial terms, including that LINNEA shall not charge more than HMR
      Bulk Market Price. In the event a controlling interest in HORMOS is
      acquired by a company operationally active in the nutraceutical and/or
      food industry the transfer of these rights shall be subject to LINNEA's
      approval, which shall not be unreasonably withheld.

2.4.  When granting sublicenses or any other right to use the Scope of the
      Agreement, LINNEA shall not grant rights exceeding or more than the rights
      granted to LINNEA with respect to Scope of the Agreement and shall cause
      the sublicense to comply with the obligations of this Agreement.

3.    OPTION RIGHTS

3.1.  LINNEA will have an exclusive option to obtain an exclusive license under
      HORMOS' Patents, Trademarks and Know-How & Documentation to the GRAS
      and/or Novel Food status including the right to market and sell
      HMRlignan(TM) in functional food applications and the right to market and
      sell the Dietary Ingredient Product where GRAS and/or Novel Food
      regulatory clearance is a prerequisite for a marketing authorisation.

3.2.  Option mechanism. LINNEA'S option right to GRAS and Novel Food status will
      expire on December 31 2007 for GRAS and December 31 2007 for Novel Food.
      If LINNEA chooses not

                                      - 4 -
<PAGE>

      to exercise these option rights, HORMOS is free to license HMRlignan(TM)
      to third parties for Functional Food applications. HORMOS shall cause the
      licensees to consider LINNEA as their supplier of HMR Bulk Ingredient in
      priority to any other manufacturers at commercially reasonable terms.

3.3.  HORMOS shall retain the non-exclusive right to manufacture or have
      manufactured the products containing HMRlignan(TM), to develop, import,
      market and distribute HMRlignan(TM) in finished forms in Functional Food
      applications and to market and sell the HMRlignan(TM) containing products
      under GRAS status on the US market. When producing such Functional Food
      products for the US market, Hormos shall purchase HMR Bulk Ingredient from
      LINNEA under reasonable commercial terms, including that LINNEA shall not
      charge more than HMR Bulk Market Price. In the event a controlling
      interest in HORMOS is acquired by a company operationally active in the
      nutraceutical and/or food industry the transfer of these rights shall be
      subject to LINNEA's approval, which shall not be unreasonably withheld.

4.    PRESCRIPTION PHARMA APPLICATIONS

      HORMOS shall retain itself all rights to develop, manufacture, market and
      distribute HMRlignan(TM) for Prescription Pharmaceutical Applications and
      the right to license said rights to third party(ies). However, unless
      agreed in writing otherwise, HORMOS shall not establish any licensing
      agreement to use HMRlignan(TM) for Prescription Pharmaceutical
      Applications before January 1 2010. LINNEA shall be preferred supplier of
      HMR Bulk Ingredient to licensees or sublicensees for Prescription
      Pharmaceutical Applications subject to LINNEA meeting necessary regulatory
      requirements.

5.    SCOPE OF THE AGREEMENT

5.1.  Subject to the terms and conditions of this Agreement, the rights and
      material to be licensed or transferred in this Agreement are detailed as
      follows and in schedules attached hereto:

5.2.  Patents. HORMOS shall grant a license to LINNEA to the Patents, including
      following patents and patent applications

      -     *****************************************************************
            ************************************************************
            ********************************************************************
            ******************* (USP ******, application No.No. US *****)

      -     ********************************************************************
            ******************* (USP ******, application No. US *****)

      -     ********************************************************** US patent
            application ***** (1st priority No. *****)

      -     ******************************************************************
            ************* (application No. US ******)

      -     *********************************** PCT/************ (1st priority
            No. *********)

      -     Lignan complexes PCT/****** (1st priority No. ******)

      -     Lignan derivatives PCT/****** (1st priority No. ******)

      -     Lignan formulations PCT/****** (1st priority No. ******)

                                      - 5 -
<PAGE>
      -     **************** PCT/****** (1st priority No. FI ******)

      -     **************** PCT/******(1st priority No. ******)

      -     **************** PCT/******(1st priority No. ******)

      -     **************** FI patent ******.

      -     **************** US patent application ******.

      -     **************** FI ******.

      The status of patent prosecution at the time of the execution of this
      Agreement is set out in Schedule 1.

5.3.  Know-how. HORMOS shall grant LINNEA access to the following know-how
      and documentation:

      5.3.1. studies sponsored by HORMOS in the following areas:

      -     General Pharmacodynamics,

      -     Toxicity

      -     Single Dose Toxicity

      -     Repeated Dose Toxicity

      -     Mutagenic Potential

      -     Pharmacokinetics

      -     Clinical Single and Repeated Dose Trials

      The Studies are detailed in Schedule 2: HMRlignan(TM) Study Archive.

      5.3.2. Written information of the manufacture of HMRlignan(TM) and its
      physicochemical properties,

5.4.  Trademarks. Subject to the terms and conditions of this Agreement, HORMOS
      grants a license to LINNEA to the following trademarks and goodwill and
      know-how associated therewith:

      -     HMRlignan(TM)

      The status of Trademark registration is set forth in Schedule 1.

5.5.  Regulatory Notification. HORMOS has obtained from the US FDA a New Dietary
      Ingredient Notification acknowledgement for HMRlignan(TM), which LINNEA
      has familiarized itself with.

5.6.  Products & Raw Material.

      5.6.1. HORMOS shall transfer ownership to LINNEA on execution of this
      Agreement, the following:

            a) approximately 10 kg of *********** complex

            b) approximately 3,000 kg chips of Norway spruce as a raw material
            for the extraction of ***********

      5.6.2. As instructed by LINNEA, HORMOS shall clearly label as belonging to
      LINNEA and store said raw material at HORMOS' premises and at HORMOS' cost
      until LINNEA requests that said raw material will be submitted by HORMOS
      to the address or place appointed by

                                      - 6 -
<PAGE>

      LINNEA and at LINNEA's cost. However, if LINNEA has not transferred said
      raw material within six months from the Date of the Agreement, HORMOS is
      entitled to destroy the raw material.

      5.6.3. The liability of the risk for the raw material passes from HORMOS
      to LINNEA upon execution of this Agreement regardless of who is managing
      the storage of the raw material.

6.    REMUNERATION

6.1.  In further consideration for the license granted, LINNEA agrees to pay
      HORMOS:

      (i)   Signing fee of 400.000 EUR within 30 days of the latest signing of
            this Agreement.

      (ii)  Running royalty of ****** (**) per cent of all Net Sales of HMR Bulk
            Ingredient produced by LINNEA or any Affiliate of LINNEA to
            unaffiliated customers or purchasers in the Patent Protection
            Territory and to whom LINNEA has granted a right to produce and
            market Dietary Supplement Product. The same royalty is payable for
            the HMR Bulk Ingredient consumed in the production of Dietary
            Supplement Products at the Bulk Market Price, if LINNEA itself or
            any of its Affiliates directly markets Dietary Supplement Products.

            The royalty is payable as from April 1, 2007 till the end of the
            Term. For avoidance of doubt, the period from the Date of this
            Agreement till March 31, 2007 is royalty free.

      (iii) Running royalty of ****** (**) per cent of all Net Sales of HMR Bulk
            ingredient produced by LINNEA or any Affiliate of LINNEA to
            unaffiliated customers or purchasers outside the Patent Protection
            Territory and in countries where a patent application based on US
            patent ***** has been rejected. In case the patent protection
            regarding any Patent or Patent application based on US patent *****
            will be restored due to appeal or other measures available, the
            royalty of fifteen (15) per cent will be paid prior and after the
            date the patent protection has been gained in that country.

            The royalty is payable as from April 1, 2007 till the end of the
            Term. For avoidance of doubt, the period from the Date of this
            Agreement till March 31, 2006 is royalty free.

      (iv)  A royalty of ****** (**) per cent for any other income LINNEA
            receives from unaffiliated customers or sublicensees of LINNEA to
            which LINNEA has sublicensed its rights to HORMOS' HMRlignan(TM)
            IPR, including but not limited to, exclusivity fees, licensing fees,
            milestone payment and royalties for the sales of Dietary Supplement
            Products, etc.

      (v)   In the event that a license from a third party is necessary to
            develop, manufacture or market HMRlignan(TM) in a certain country or
            territory due to third party dominating proprietary intellectual
            property rights, LINNEA may offset against royalties payable to
            HORMOS any payments made due to such third party intellectual
            property rights, provided that HORMOS has given its prior written
            consent, which consent shall not be

                                      - 7 -
<PAGE>

            unreasonably withheld and that in no event shall the royalty due to
            HORMOS be reduced more than down to ****** (**) per cent.

      (vi)  For the avoidance of doubt, for each Product the Net Sales shall be
            calculated only once for the first sale of such Product by either
            LINNEA or its Affiliate to a customer.

      (vii) In consideration of expenses incurred by LINNEA during the startup
            period, HORMOS will credit LINNEA against first due royalty payments
            sum of EUR ****** of the first payable royalty payments.

6.2.  Any royalty payable hereunder shall be due and paid yearly within 60 days
      after the end of each 6-months period commencing the effective date of
      this agreement. Together with the royalty payments, LINNEA shall provide
      HORMOS with calculation and specification for accrued royalties and yearly
      volume of sales of HMR Bulk Ingredient.

      LINNEA shall keep and require its Affiliated Companies and sublicensees to
      keep and maintain complete and accurate records and books of account in
      sufficient detail and form so as to enable verification of royalties paid
      or payable hereunder. Not more often than once a year LINNEA shall allow
      and arrange HORMOS to audit its own or its Affiliated Company's and/or
      sublicensees' records and books of account for correctness of royalty
      payments and Net Sales, if requested and at the auditing party's expense.

      All payments, once made, shall be non-refundable.

6.3.  Prior to LINNEA or any of its sublicensees start to commercially exploit
      the Patents, LINNEA undertakes to inform HORMOS in writing which are the
      Patents to be exploited, and if requested by HORMOS, how the Patents are
      exploited.

6.4.  Remuneration for option rights. In case LINNEA decides to exercise its
      exclusive option to sell Products under GRAS or Novel Food status, LINNEA
      agrees to pay HORMOS:

      (i)   ***** USD for GRAS status, and

      (ii)  ***** USD for Novel Food status

      If LINNEA decides to exercise its option rights, ** % of the applicable
      fee in both cases (i) and (ii) will be payable at filing of GRAS/Novel
      Food application and ** % on approval.

7.    PERFORMANCE MILESTONES

7.1.  If LINNEA do not achieve either or both of the following yearly minimum
      volumes with regard to the sales of HMR Bulk Ingredient for year 2006 or
      any year onwards, then the Parties shall discuss in good faith necessary
      measures to improve the volume of sales. If the result of discussions do
      not satisfy HORMOS, and failure to meet yearly minimum volumes is not a
      direct result of act or negligence of HORMOS, then HORMOS shall have the
      right to unilaterally terminate the exclusivity of licensed rights with
      regard to Dietary Supplement Products or products requiring GRAS/Novel
      Food status or both, as the case may be, and HORMOS will be entitled in
      its sole discretion to discuss, negotiate and enter into an agreement(s)
      with third parties regarding grant of licenses or sublicenses for its
      HMRlignan(TM) and the Scope of the Agreement. For avoidance of doubt, if
      LINNEA has failed to meet the

                                      - 8 -
<PAGE>

      yearly Performance Milestones of sales of HMR Bulk Ingredient for either
      Dietary Supplement Products or products requiring GRAS/Novel Food status,
      but not both, LINNEA shall maintain the exclusivity for the products it
      has reached the yearly Performance Milestones. However, even after losing
      the exclusivity for the production of certain products, LINNEA will remain
      a preferred manufacturer and supplier of HMR Bulk Ingredient to HORMOS'
      new licensees or sublicensees subject to agreeable commercial terms and
      conditions.

7.1.1. The yearly Performance Milestones for Dietary Supplement Products:

      (i)   *** kg sales minimum ****

      (ii)  *** kg sales minimum ****

      (iii) *** kg sales minimum ****

7.1.2. In the event either of the GRAS/Novel Food options is exercised the
      additional yearly Performance Milestones are as follows:

      (iv)  *** kg sales minimum *****

      (v)   *** kg sales minimum *****

      (vi)  *** kg sales minimum *****

8.    BEST ENDEAVOURS

8.1   LINNEA shall use commercially reasonable efforts to (i) introduce
      HMRlignan(TM) into commercial market as soon as practical, (ii) to develop
      and exploit herein licensed rights by manufacture and sale of HMR Bulk
      Ingredient throughout the territory during the Term of this Agreement,
      (iii) to control the quality of the products, and (iv) properly, safely,
      fairly and lawfully to develop and exploit the market in the territory for
      the products.

8.2   Failure of LINNEA to comply with previous clause 8.1 shall entitle HORMOS
      to unilaterally terminate the exclusive nature of this Agreement and
      HORMOS will be entitled in its sole discretion to discuss, negotiate and
      enter into an agreement(s) with third parties regarding grant of licenses
      or sublicenses for its HMRlignan(TM) and the Scope of the Agreement

9.    PROSECUTION AND MAINTENANCE OF INTELLECTUAL PROPERTY RIGHTS

9.1   For the Term of this Agreement, HORMOS shall prosecute and maintain in
      force the Patents and Trademarks in accordance with the instructions of
      LINNEA. LINNEA shall be responsible for all decision making related to the
      Patents and related to patenting strategy after the Date of the Agreement.
      After approval of yearly patent budget in advance, LINNEA shall compensate
      HORMOS for all external costs arising out of or related to the prosecution
      of Patent applications and maintenance of issued Patents. In case LINNEA
      chooses not to pay the prosecution or maintenance of any of the Patents,
      LINNEA shall inform HORMOS in writing and in good time prior to any
      deadlines, and HORMOS is entitled but not obliged to give up the
      prosecution or maintenance of these Patents. HORMOS may choose at its cost
      and responsibility to prosecute or maintain the Patents, whose maintenance
      LINNEA has given up.

                                      - 9 -
<PAGE>

9.2   Trademarks. After the execution of this Agreement, LINNEA shall be
      entitled to exploit the Trademarks in its sole discretion but in a good
      and respectful manner.

10.   WARRANTIES

10.1. Warranties. Both HORMOS and LINNEA warrant they have the right to execute
      and effect this Agreement.

      HORMOS represents and warrants in respect to the Scope of the Agreement,
      including the Patents, that as of the Date of this Agreement:

      a)    it has a legal power to grant license with regard to the Patents and
            Trademarks;

      b)    it has good and marketable title to the Scope of the Agreement;

      c)    it has not made and will not make any commitments to others
            inconsistent with or in derogation of the rights granted hereunder
            to LINNEA;

      d)    and that the Patents are free and clear from any encumbrances,
            liens, pledges or licenses;

      e)    to the best of HORMOS' knowledge, HORMOS has acquired shares of all
            the respective inventors of each invention in the Patents;

      f)    there are no patent infringement suits or asserted patent
            infringement claims pertaining to the Patents pending on the date of
            execution of this Agreement.

      g)    to Hormos' knowledge Patents and Trademarks do not infringe rights
            of third parties, excluding identified potentially overlapping
            patents set forth in Schedule 3,

      h)    it has given to LINNEA all the relevant know-how and information in
            written form described in section 5.3 in its possession.

10.2. Negation of Implication by HORMOS.

      Nothing in this Agreement shall be construed as

      a)    A warranty or representation by HORMOS as to the validity or scope
            of any licensed Patent; or

      b)    A warranty or representation that anything made, used, sold or
            otherwise disposed of under any of the Patents and Trademarks is or
            will be free from infringement of third parties; or

      c)    A requirement that HORMOS shall file any Patent application, secure
            any Patent or Trademark, or maintain any Patent or Trademark in
            force, unless so agreed in section 9.1 of this Agreement or in
            writing; or

      d)    An obligation to bring or prosecute actions or suits against third
            parties for infringement of Patents or Trademarks; or

      E)    WARRANTY OR REPRESENTATION OF THE FITNESS, SUITABILITY OR USEFULNESS
            OF ANY OF THE SCOPE OF THIS AGREEMENT FOR ANY PURPOSE, OR REGARDING
            ANY OTHER MATTER, AND ANY REPRESENTATION OR WARRANTY BY OR ON BEHALF
            OF HORMOS WHICH IS NOT EXPRESSLY STATED HEREIN, IS DISCLAIMED,
            INCLUDING WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF
            MERCHANTABILITY OF FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE
            OF THE patents WILL NOT INFRINGE ANY THIRD PARTY PATENT OR
            INTELLECTUAL PROPERTY RIGHT.

                                     - 10 -
<PAGE>

10.3. LINNEA warrants that upon the execution of this Agreement, it has received
      all relevant Know-How & Documentation described in section 5.3.

11.   APPLICABLE LAW AND DISPUTE RESOLUTION

11.1. This Agreement shall be construed and governed by English law without
      giving effect to the choice of law provisions thereof (and without
      limiting the foregoing, the United Nations Convention on Contracts for
      International Sale of Goods shall not govern this Agreement).

11.2  If after discussion concerning any difference, dispute or question arising
      in connection with this Agreement HORMOS and LINNEA are unable to reach
      agreement, the matter shall be finally and exclusively settled by binding
      arbitration under the Rules of Arbitration of the International Chamber of
      Commerce. The arbitration shall take place in Stockholm, Sweden in the
      English language.

      The decision will be made by a sole arbitrator appointed in accordance
      with applicable Rules, unless the Parties agree in writing that there will
      more than one arbitrator. The decision of the arbitrator(s) shall be
      binding and conclusive on the Parties, and they shall comply with such
      decision in good faith.

12.   LIABILITY AND TERMINATION

12.1  If a Party is in Material Breach of its obligations under this Agreement
      or repeatedly breaches the terms of this Agreement, and such default is
      not cured within thirty (30) days from the date the written notice thereof
      has been dispatched, the other Party (the non-breaching Party) is entitled
      to terminate this Agreement with immediate effect.

12.2  If a Party is apparently insolvent, declared bankrupt or in a debt
      restructuring procedure, the other Party may with written notice terminate
      this Agreement immediately, unless the insolvent Party gives satisfactory
      guarantees that the Agreement is unaffected by said insolvency.

12.3  For the damages incurred by the non-breaching Party caused by the material
      breach of this Agreement, the non-breaching Party shall be entitled to
      receive compensation from the breaching Party. The breaching Party shall
      be liable for actual and direct damages to the other Party. Parties are
      not, however, liable for any punitive, indirect or consequential damages,
      including but not limited to loss of profits, arising from this Agreement.
      Except as otherwise provided in section 11 below, the Parties' liability
      towards each other shall be limited to the amount of ******
      (*******) euro.

12.4  During the Term LINNEA may terminate without any cause this Agreement at
      any time by giving HORMOS a written notice 4 months prior to such
      termination will become effective. On effective day, any and all rights
      granted under this Agreement by HORMOS to LINNEA will be returned back to
      HORMOS and LINNEA shall not retain itself any rights with regard to HMR
      Bulk Ingredient or HMRlignan(TM). In connection with such termination
      LINNEA shall assign HORMOS a right to any improvement or intellectual
      property right necessary for the development, manufacture or
      commercialisation of HMR Bulk Ingredient or HMRlignan(TM) and all the HMR
      Bulk Ingredients in its possession.

13.   ASSIGNMENT

                                     - 11 -
<PAGE>

      The obligations toward the other Party set out in this Agreement are
      deemed personal to the Parties. Therefore, neither Party shall, without
      the prior written consent of the other Party, assign its rights or
      obligations to any third party. Such consent shall not be withheld if the
      non-assigning Party receives and accepts such written assurances of
      continued performance and commitments from the assignee as it may
      reasonably require or if such an assignment is contemplated in connection
      with the sale or merger by a Party of all or substantially all of its
      assets to a third party or if such an assignment is made to an Affiliate
      of the Party.

      For avoidance of doubt, aforementioned does not restrict LINNEA to
      exercise its right to grant sublicenses to third parties subject to terms
      and conditions of this Agreement.

14.   INDEMNITY FOR PRODUCT LIABILITY

      LINNEA agrees to indemnify, defend and hold HORMOS, its Affiliates and its
      and their directors, officers, employees and shareholders harmless from
      and against any and all third party claims, suits, proceedings, demands,
      liabilities or expenses (including reasonable legal fees) related to
      actual or alleged injury, damage, death or other consequence, including
      product liability, occurring to any legal or natural person or property,
      as result, directly or indirectly, of the possession, use or consumption
      of HMR Bulk Ingredient or Dietary Supplement Product actually manufactured
      or sold by Linnea, its Affiliates or its sublicensees. Without limiting
      the generality of the foregoing, LINNEA shall not indemnify HORMOS in
      respect of claims and suits for injury and damages caused by HORMOS'
      failure to provide LINNEA with necessary information in its possession,
      fraud, negligence or wilful misconduct of HORMOS or its employees or
      directors or caused by raw material provided by HORMOS.

15.   INFRINGEMENT OF INTELLECUAL PROPERTY RIGHTS

15.1. Infringement of Patents, Trademarks and Know-How

      Each Party shall report promptly in writing to other Party any known or
      suspected infringement of any Patents, Trademarks, Know-How or other
      intellectual property right included in the Scope of the Agreement.

      LINNEA shall have the first right to commence any proceedings anywhere in
      the world against infringing third party. LINNEA shall keep HORMOS
      informed promptly of status of such actions. HORMOS shall have a right to
      participate and be represented in any proceedings by its own counsel at
      its own expense. LINNEA shall not settle any such proceedings involving
      the Patents or Trademarks without obtaining HORMOS' prior written consent,
      which consent shall not be unreasonably withheld. If LINNEA shall not take
      any action, it shall inform HORMOS within 30 days after it has become
      aware of such infringement, and HORMOS has a secondary right, at its
      expense, to any action due to such infringement.

15.2. Alleged Infringement of third party rights

      If a third party notifies a Party, Affiliate or a sublicensee of, or
      commences proceedings for, an alleged infringement of the third party
      intellectual property rights or unauthorised use of its technology arising
      out of development, manufacture, use, sale or marketing of HMRlignan(TM),
      HMR Bulk Ingredient or Dietary Supplement Products or Patent validity
      related actions, that Party shall notify the other Party promptly of claim
      or the commencement of such proceedings.

                                     - 12 -
<PAGE>

      At LINNEA's request HORMOS shall advise LINNEA regarding the technical
      merits of such claim.

      LINNEA agrees to indemnify, defend and hold HORMOS, its Affiliates and its
      and their directors, officers, employees and shareholders harmless from
      and against any and all third party claims, suits, proceedings, demands,
      liabilities or expenses (including reasonable legal fees) related to
      infringement of third party's intellectual property rights or unauthorised
      use of its proprietary technology arising out of development, manufacture,
      use, sale or marketing of HMRlignan(TM), HMR Bulk Ingredient or Dietary
      Supplement Products by LINNEA, its Affiliate or its sublicensees or Patent
      validity related actions, provided that LINNEA has sole control of and
      authority over the defence or settlement of the proceedings and HORMOS
      cooperates with respect to technical merits of said claim. Without
      limiting the generality of the foregoing, LINNEA shall not indemnify
      HORMOS in respect of claims and suits related to infringement of third
      party's intellectual property rights if HORMOS has failed to disclose to
      LINNEA information of infringements of third party rights known by HORMOS
      at the Date of the Agreement

      Nothing herein shall be interpreted as an indemnity by a Party in respect
      of claims and suits for injury and damages caused by fraud, negligence,
      failure or wilful misconduct of the other Party or its employees or
      directors.

15.3  HORMOS shall neither have any obligations to defend any Patents, nor
      compensate for or indemnify, defend or hold harmless LINNEA, LINNEA
      Affiliates or LINNEA's sublicensees or customers against any claim, third
      party infringement claim or other claim.

16.   CONFIDENTIALITY

      HORMOS and LINNEA have entered into a Confidentiality Agreement on 20
      March 2003. The Parties agree to treat all Confidential Information
      already disclosed as Confidential Information. In addition, in the future
      the Parties may receive Confidential Information from the other Party
      related to the further development of HMRlignan(TM) or their trade secrets
      or business activities. Both Parties warrant that they shall treat such
      information as confidential and that they shall not:

      a)    use such information to any other purpose but to exercise their
            rights, fulfill their obligations as set out in this Agreement or as
            agreed separately, as the case may be, and

      b)    disclose received information to any third party without prior
            written consent of the other Party, acquired separately for each
            disclosure of information.

      To the extent it can be established by sufficient evidence, the
      obligations set forth in this Agreement shall not apply to:

            1)    information which at the time of the disclosure hereunder is
                  in the public domain; or

            2)    information which, after disclosure hereunder, becomes part of
                  the public domain in other way than by faults of the receiving
                  Party; or

            3)    information which has already been in the possession of the
                  Party at the time of disclosure hereunder, or

                                     - 13 -
<PAGE>

            4)    information which a Party receives from a third party who is
                  not under any obligation of secrecy towards the other Party;
                  or

            5)    information which has been independently conceived or
                  developed by the receiving Party without breach of the
                  confidentiality obligations.

17.   FORCE MAJEURE

      Force majeure is an event that prevents the performance or causes
      unreasonable difficulties for the fulfilment of that Party's obligations
      under this Agreement, such as war, riot, acts of God, fire, and
      interruption of the energy delivery, strike, blockade or other equally
      important and unusual cause beyond the affected Party's control. The Party
      (or Affiliates) affected by Force Majeure shall not be liable for any
      delays or failures to perform the obligations under this Agreement. The
      Party affected by the force majeure is entitled to postpone its
      performance as long as Force Majeure event continues. If the Force Majeure
      event continues more than five (5) months, either Party may terminate this
      Agreement immediately by giving written notice to the other Party.

18.   MISCELLANEOUS

18.1. Non-waiver

      Either Party's failure to exercise or enforce any right conferred upon it
      hereunder shall not be deemed to be a waiver of any such right unless
      specifically so stipulated or operate to bar the exercise of performance
      thereof at any time or times thereafter, nor shall its waiver of any right
      hereunder at any given time, including rights to any payment, be deemed a
      waiver thereof for any other time.

18.2. Severability

      In case any provision of this Agreement shall be invalid, illegal or
      unenforceable due to the legislation of Finland, Switzerland, the European
      Union or the USA, such invalidity, illegality or unenforceability shall
      not affect any other provision hereof. The Parties shall negotiate in good
      faith in order to agree the terms of a mutually satisfactory provision to
      be substituted for the provision which is invalid, illegal of
      unenforceable and which as nearly as possible validly gives effect to the
      Parties' intentions as expressed herein.

18.3. Headings

      All section headings in this Agreement are for convenience only and shall
      not in any way affect the meaning or interpretation of the Agreement.

18.4. Entire Agreement and Amendments

      This Agreement, together with all Appendices and Schedules hereto,
      represents the full and complete understanding and agreement of the
      Parties pertaining to the subject matter hereof and prevails over all
      statements, clauses or conditions which may be contained in any other form
      or document. No modifications and amendments to this Agreement shall be
      valid unless made in writing and signed by duly authorized representatives
      of LINNEA and HORMOS.

19.   NOTICES

      Notices provided hereunder and concerning validity or term of this
      Agreement are to be given

                                     - 14 -
<PAGE>

      by either Party to the other shall be in writing and shall be given in
      person or be prepaid registered mail to the respective addresses or to
      such other addresses as the Parties may hereafter communicate to each
      other in writing.

      Notices to LINNEA shall be sent to: LINNEA S.A.
                                          Via Cantonale, 6595 Riazzino (Locarno)
                                          Switzerland
                                          Telefax:

      Notices to HORMOS shall be sent to: Hormos Medical Corporation
                                          PharmaCity, Itainen Pitkakatu 4
                                          FIN-20520 Turku, Finland
                                          Telefax: 358 2 410 8001

20.   SIGNATURES

      This Agreement has been duly executed in duplicate copies, one retained by
      both contracting Parties.

      LINNEA S.A.

      By:  /s/ Michael Granville
           ---------------------

      Name:  Michael Granville

      Title: President (Authorized Signatory)

      HORMOS MEDICAL CORPORATION

      By:  /s/ Risto Lammintausta
           ----------------------

      Name: Risto Lammintausta

      Title: Chief Executive Officer (Authorised Signatory)

SCHEDULES:

Schedule 1: Current Patent and Trademark Status

Schedule 2: HMRlignan(TM) Study Archive

Schedule 3: List of potentially overlapping patents of third parties known by
            HORMOS

                                     - 15 -
<PAGE>

                                                                      SCHEDULE 1

CURRENT PATENT AND TRADEMARK STATUS 9.4.2005

PATENTS

INVENTION ID      *******

TITLE             *************

<TABLE>
<CAPTION>

COUNTRYCOD  COUNTRYNAME         CASE    APPLICANTID   APPLDATE    APPLNO        STATUS   PATNO  EXPIREDA  1PRIONUMBER     1PRIODAY
<S>         <C>                 <C>     <C>           <C>         <C>           <C>      <C>    <C>       <C>             <C>
*****        *****              *****     *****        *****       *****         *****                    *****           *****
*****        *****              *****     *****        *****       *****         *****
</TABLE>

INVENTIONID       HM-3O001

TITLE             **************************************************************
                  **************************************************************
                  ****************

<TABLE>
<CAPTION>

COUNTRYCOD  COUNTRYNAME      CASE    APPLICANTID   APPLDATE    APPLNO        STATUS    PATNO    EXPIREDA    1PRIONUMBER   1PRIODAY
<S>         <C>              <C>     <C>           <C>         <C>           <C>       <C>      <C>         <C>           <C>
*****        *****           *****   *****         *****       *****         *****     *****    *****       *****         ****
*****        *****           *****   *****         *****       *****         *****                          *****         ****
*****        *****           *****   *****         *****       *****         *****                          *****         ****
*****        *****           *****   *****         *****       *****         *****     *****    *****       *****         ****
*****        *****           *****   *****         *****       *****         *****                          *****         ****
*****        *****           *****   *****         *****       *****         *****     *****    *****       *****         ****
*****        *****           *****   *****         *****       *****         *****     *****    *****       *****         ****
*****        *****           *****   *****         *****                     *****                          *****         ****
*****        *****           *****   *****         *****       *****         *****                          *****         ****
*****        *****           *****   *****         *****       *****         *****                          *****         ****
*****        *****           *****   *****         *****       *****         *****                          *****         ****
*****        *****           *****   *****         *****       *****         *****                          *****         ****
*****        *****           *****   *****         *****       *****         *****              *****       *****         ****

</Table>
<PAGE>
                                                                      SCHEDULE 1

<TABLE>
<CAPTION>

COUNTRYCOD  COUNTRYNAME         CASE    APPLICANTID   APPLDATE   APPLNO         STATUS    PATNO   EXPIREDA   1PRIONUMBER   1PRIODAY
<S>         <C>                 <C>     <C>           <C>        <C>            <C>       <C>     <C>        <C>          <C>
*****       *****               *****   ******        *****      *****          *****                        *****         *****

*****       *****               *****   ******        *****      *****          *****                        *****         *****

*****       *****               *****   ******        *****      *****          *****                        *****         *****

*****       *****               *****   ******        *****      *****          *****     *****   *****      *****         *****

*****       *****               *****   ******        *****      *****          *****     *****   *****      *****         *****

*****       *****               *****   ******        *****      *****          *****                        *****         *****

*****       *****               *****   ******        *****      *****          *****     *****   *****      *****         *****

*****       *****               *****   ******        *****      *****          *****     *****   *****

*****       *****               *****   ******        *****      *****          *****                        *****         *****
</Table>

INVENTIONID       *****

TITLE             ****************

<TABLE>
<CAPTION>

COUNTRYCOD  COUNTRYNAME         CASE   APPLICANTID   APPLDATE    APPLNO         STATUS    PATNO   EXPIREDA   1PRIONUMBER  1PRIODAY
<S>         <C>                 <C>    <C>           <C>         <C>            <C>       <C>     <C>        <C>          <C>
*****       *****               *****  *****         *****       *****          *****                        *****        *****

*****       *****               *****  *****         *****       *****          *****                        *****        *****

*****       *****               *****  *****         *****       *****          *****     *****   *****
</TABLE>

INVENTIONID       ******

TITLE             ***********

<TABLE>
<CAPTION>

COUNTRYCOD  COUNTRYNAME  CASE   APPLICANTID   APPLDATE    APPLNO   STATUS   PATNO    EXPIREDA    1PRIONUMBER  1PRIODAY
<S>         <C>          <C>    <C>           <C>         <C>      <C>      <C>      <C>         <C>          <C>
*****       *****        *****  *****         *****       *****    *****    *****    *****
</TABLE>
<PAGE>
                                                                      SCHEDULE 1

INVENTIONID       *****

TITLE             ************

<TABLE>
<CAPTION>

COUNTRYCOD  COUNTRYNAME         CASE   APPLICANTID   APPLDATE    APPLNO         STATUS     PATNO  EXPIREDA   IPRIONUMBER  IPRIODAY
<S>         <C>                 <C>    <C>           <C>         <C>            <C>        <C>    <C>        <C>          <C>

****        ****                ****   ****          ****        ****           ****                         ****         ****

****        ****                ****   ****          ****        ****           ****       ****   ****

****        ****                ****   ****          ****        ****           ****                         ****         ****

****        ****                ****   ****          ****        ****           ****                         ****         ****
</TABLE>

INVENTIONID       *****

TITLE             ************

<TABLE>
<CAPTION>

COUNTRYCOD  COUNTRYNAME  CASE   APPLICANTID  APPLDATE    APPLNO    STATUS   PATNO  EXPIREDA  IPRIONUMBER  IPRIODAY
<S>         <C>          <C>    <C>          <C>         <C>       <C>      <C>    <C>       <C>          <C>
****        ****         ****   ****         ****        ****      ****

</TABLE>

INVENTIONID       ******

TITLE             ******

<TABLE>
<CAPTION>

COUNTRYCOD COUNTRYNAME        CASE   APPLICANTID  APPLDATE   APPLNO         STATUS     PATNO     EXPIREDA    IPRIONUMBER  1PRIODAY
<S>        <C>                <C>    <C>          <C>        <C>            <C>        <C>       <C>         <C>          <C>
****       ****               ****   ****         ****       ****           ****                             ****         ****

****       ****               ****   ****         ****       ****           ****       ****      ****

****       ****               ****   ****         ****       ****           ****                             ****         ****

****       ****               ****   ****         ****       ****           ****                             ****         ****
</TABLE>

INVENTIONID       *******

TITLE             **************

<TABLE>
<CAPTION>

COUNTRYCOD COUNTRYNAME CASE   APPLICANTID  APPLDATE   APPLNO      STATUS    PATNO  EXPIREDA  IPRIONUMBER  IPRIODAY
<S>        <C>         <C>    <C>          <C>        <C>         <C>       <C>    <C>       <C>          <C>
*****      *****       *****  *****        *****      *****       *****
</TABLE>

<PAGE>

                                                                  SCHEDULE 1
<TABLE>
<CAPTION>

INVENTIONID     *******
TITLE           *******

COUNTRYCOD  COUNTRYNAME         CASE  APPLICANTID    APPLDATE APPINO            STATUS     PATNO   EXPIREDA  1PRIONUMBER  1PRIODAY
<S>         <C>                 <C>                   <C>                        <C>        <C>     <C>      <C>          <C>
*******     *******             ***** *******        *******  *******           *******                      *******      *******

*******     *******             ***** *******        *******  *******           *******                      *******      *******

*******     *******             ***** *******        *******  *******           *******                      *******      *******
</TABLE>

<TABLE>
<CAPTION>

INVENTIONID     *******
TITLE           *******

COUNTRYCOD  COUNTRY NAME        CASE  APPLICANTID    APPLDATE APPINO            STATUS     PATNO   EXPIREDA  1PRIONUMBER  IPRIODAY
<S>         <C>                 <C>                  <C>                        <C>         <C>     <C>      <C>          <C>
*******     *******             ***** *******        *******  *******           *******                      *******      *******

*******     *******             ***** *******        *******  *******           *******

*******     *******             ***** *******        *******  *******           *******                      *******      *******

*******     *******             ***** *******        *******  *******           *******                      *******      *******

</TABLE>

<TABLE>
<CAPTION>

INVENTIONID ************
TITLE       ************

COUNTRYCOD  COUNTRYNAME         CASE    APPLICANTID  APPLDATE APPINO            STATUS     PATNO   EXPIREDA  1PRIONUMBER  1PRIODAY
<S>         <C>                 <C>                  <C>                        <C>         <C>     <C>       <C>         <C>
*******     *******             ******* *******      *******  *******           pending

</TABLE>
<PAGE>
                                                                      SCHEDULE 1

<TABLE>
<CAPTION>

INVENTIONID      ********
TITLE            ********

COUNTRYCOD  COUNTRYNAME         CASE    APPLICANTID  APPLTIATE APPINO           Status     PATNO   EXPIREDA  1PRIONUMBER  1PRIODAY
<S>         <C>                 <C>                  <C>                        <C>        <C>     <C>       <C>          <C>
*******     *******             ***** *******        *******  *******           *******                      *******      *******

*******     *******             ***** *******        *******  *******           *******    ******* *******

*******     *******             ***** *******        *******  *******           *******                      *******      *******

*******     *******             ***** *******        *******  *******           *******                      *******      *******

</TABLE>

<TABLE>
<CAPTION>

INVENTIONLID      *******
TITLE             *******

COUNTRYCOD  COUNTRYNAME         CASE    APPLICANTID  APPLDATEAPPINO             STATUS     PATNO   EXPIREDA  1PRIORNUMBER 1PRIODAY
<S>         <C>                 <C>                  <C>                        <C>        <C>     <C>       <C>          <C>
*******     *******             ***** *******        *******  *******           *******                      *******      *******

*******     *******             ***** *******        *******  *******           *******    ******                         *******

*******     *******             ***** *******        *******  *******           *******                      *******      *******

*******     *******             ***** *******        *******  *******           *******                      *******      *******

</TABLE>

<TABLE>
<CAPTION>

INVENTIONID      ********
TITLE            ********

COUNTRYCOD  COUNTRYNAME         CASE    APPLICANTID  APPLDATE APPINO            STATUS     PATNO   EXPIREDA  IPRIONUMBER  1 PRIODAY
<S>         <C>                 <C>                  <C>                        <C>        <C>     <C>       <C>          <C>
*******     *******             ***** *******        *******  *******           *******                      *******      *******

*******     *******             ***** *******        *******  *******           *******    ******* *******

*******     *******             ***** *******        *******  *******           *******                      *******      *******

*******     *******             ***** *******        *******  *******           *******                      *******      *******

</TABLE>
<PAGE>
                                                           SCHEDULE 1
TRADEMARKS

US trademark application No. 78/294,174, filed 29 Aug 2003 for the wordmark
"HMRlignan" in classes 1 and 5. Notice of Allowance issued on November 30,2004.
The registration will be postponed until a Statement of Use is filed.

<PAGE>
                                                                      SCHEDULE 2

<TABLE>
<S>     <C>        <C>    <C>        <C>     <C>     <C>       <C>             <C>        <C>     <C>
STUDY   OLD STUDY  TITLE  PROTOCOLL  DRAFT   FINAL   STUDY     LABORATORY/CRO  CRO STUDY  AMEND.  COMMENTS
NUMBER  NUMBER                       REPORT  REPORT  DIRECTOR                  NUMBER
</TABLE>

(HORMOS LOGO)

HMRLIGNAN(TM) STUDY ARCHIEVE

<Table>
<Caption>
STUDY                                             STUDY CODE          OLD CODE
-----                                             ----------          --------
<S>                                               <C>                 <C>
*****                                             *****               *****

*****                                             *****               *****

*****                                             *****               *****

*****                                             *****               *****

*****                                             *****               *****

*****                                             *****               *****

*****                                             *****               *****

*****                                             *****               *****

*****                                             *****               *****
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
STUDY   OLD STUDY       TITLE                                    PROTOCOLL   DRAFT       FINAL       STUDY        LABORATORY/CRO
NUMBER  NUMBER                                                               REPORT      REPORT      DIRECTOR
<S>     <C>             <C>                                      <C>         <C>         <C>         <C>          <C>

Chemical and pharmaceutical documentation=II

General Pharmacodynamics= ******

****        ****        ****                                     ****                    ****        ****         ****

****        ****        ****                                     ****                    ****        ****         ****

****        ****        ****                                     ****                    ****        ****         ****

****        ****        ****                                     ****                    ****        ****         ****

****        ****        ****                                     ****                    ****        ****         ****

****        ****        ****                                     ****                    ****        ****         ****

****        ****        ****                                     ****                    ****        ****         ****

****        ****        ****                                     ****                    ****        ****         ****

****        ****        ****                                     ****        ****        ****        ****         ****

****        ****        ****                                     ****        ****        ****        ****         ****
</TABLE>

<TABLE>
<CAPTION>
STUDY   CRO STUDY    AMEND.  COMMENTS
NUMBER  NUMBER
<S>     <C>          <C>     <C>

Chemical and pharmaceutical documentation=II

General Pharmacodynamics= ******

 ****   ****                 ****

 ****   ****                 ****

 ****   ****                 ****

 ****   ****                 ****

 ****   ****                 ****

 ****   ****                 ****

 ****   ****                 ****

 ****   ****                 ****

 ****   ****                 ****

 ****   ****                 ****

</TABLE>
<PAGE>
<TABLE>
<CAPTION>
STUDY   OLD STUDY       TITLE                                    PROTOCOLL   DRAFT       FINAL        STUDY        LABORATORY/CRO
NUMBER  NUMBER                                                               REPORT      REPORT       DIRECTOR
<S>     <C>             <C>                                      <C>         <C>         <C>          <C>          <C>
Toxicity= 44, Single Dose Toxicity 441, Repeated Dose Toxicity 442 (Old Code: IIIA)

*****    *****          *****                                                            *****        *****        *****

*****    *****          *****                                                *****       *****        *****        *****

*****    *****          *****                                    *****       *****       *****        *****        *****

****     *****          *****                                    *****       *****       *****        *****        *****

****     *****          *****                                    *****       *****       *****        *****        *****

****     *****          *****                                                            *****        *****        *****

*****    *****          *****                                    *****                   *****        *****        *****

****     *****          *****                                    *****                   *****        *****        *****

*****************************

****     *****          *****                                    *****                   *****        *****        *****

****     *****          *****                                    *****        *****      *****        *****        *****

****     *****          *****                                    *****                   *****        *****        *****
</TABLE>

<TABLE>
<CAPTION>
STUDY   CRO STUDY  AMEND.  COMMENTS
NUMBER  NUMBER
<S>     <C>        <C>     <C>
Toxicity= 44, Single Dose Toxicity 441, Repeated Dose Toxicity 442 (Old Code: IIIA)

*****                      *****

*****                      *****

*****   *****      *****   *****

*****   *****      *****   *****

*****   *****      *****   *****

*****

*****              *****

********************************

*****   *****      *****   *****

*****   *****      *****

*****   *****
</TABLE>

<PAGE>
<TABLE>
<CAPTION>
STUDY     OLD STUDY      TITLE                                     PROTOCOLL  DRAFT  FINAL
NUMBER    NUMBER                                                              REPORT REPORT
<S>       <C>            <C>                                       <C>        <C>    <C>
******

******

</TABLE>

<TABLE>
<CAPTION>
STUDY     STUDY       LABORATORY/CRO CRO STUDY AMEND.  COMMENTS
NUMBER    DIRECTOR                   NUMBER
<S>       <C>         <C>            <C>       <C>     <C>
******

</TABLE>

<PAGE>

<TABLE>
<CAPTION>
STUDY     OLD STUDY      TITLE                                     PROTOCOLL  DRAFT  FINAL
NUMBER    NUMBER                                                              REPORT REPORT
<S>       <C>            <C>                                       <C>        <C>    <C>

*****

</TABLE>

<TABLE>
<CAPTION>
STUDY     STUDY       LABORATORY/CRO CRO STUDY AMEND.  COMMENTS
NUMBER    DIRECTOR                   NUMBER
<S>       <C>         <C>            <C>       <C>     <C>

*****

</TABLE>

<PAGE>

                                                                      SCHEDULE 3

Potentially overlapping patents of third parties known by HORMOS

1.      Country:          *****
        Inventors:        *********
        Title:            *********
                          *********
                          *********
        Patent Assignee:  ********
        Patent no:        ******<PAGE>
                                                                  Exhibit 10.19

                               September 29, 2003

Gary Onn

Dear Gary:                                                    24420 SE 4th Court

                                                              Issaquah, WA 98029

     This letter ("Agreement") sets forth terms and conditions which will apply
to your performance of services for QuatRx Pharmaceuticals Company ("QuatRx"),
which will commence November 1, 2003. You and QuatRx acknowledge as follows:

     I. POSITION AND RESPONSIBILITIES. YOU will serve in the capacity of Chief
Financial Officer and report to Dr. Robert L. Zerbe, President and CEO.

     You will also work in cooperation with other QuatRx officers and employees.
You will perform and discharge such other reasonable responsibilities and duties
as may be assigned to you. You will perform your duties to the best of your
ability during your employment. You will devote your full working time,
attention and energies to, and use your best efforts, ability and fidelity in
the performance of, your duties and obligations.

     2. COMPENSATION AND BENEFITS.

     (a) Salary. You will be paid a salary at the rate of $175,000 per year
during the continuance of your employment or such other salary as may
subsequently be agreed to by you and QuatRx, acting through its Board of
Directors. Salary will be paid monthly in arrears. Your salary will he reviewed
and subject to change at least annually.

     (h) Benefits. You will receive such benefits, including without limitation
bonus, retirement/401(k). health insurance and vacation, as are similar to the
range of benefits afforded to other employees of QuatRx at similar levels of
responsibility and which are approved by QuatRx. (c) Business Expenses. Upon
submission of proper documentation and in accordance with the standard written
policies of QuatRx, you will be reimbursed for all ordinary and necessary
business expenses or business related entertainment expenses incurred in
connection with the performance of the services to be provided by you under this
Agreement.

     (d) Relocation Allowance. You will be provided a net expense allowance of
$25,000, payable in cash and without withholding upon your joining the Company,
to use in your discretion for expenses you incur in connection with your
relocation and travel between the Company's offices and your current residence,
including without limitation air travel for you and your family, lodging and
other travel expenses, moving costs, establishment of a second residence and
related fees and expenses, and other costs that you incur that are reasonably
related to your relocation and the establishment and maintenance of a second
residence. The

<PAGE>

amount of the allowance payment will he grossed up so that the net amount
realized by you after taxes is $25,000.

     (e) Realtor Allowance. You will be reimbursed up to $35,000, before
gross-up for income and employment related taxes, for commissions actually paid
by you to real estate sales agents in connection with the sale of your current
principal residence occurring while you are employed by the Company.
Reimbursement will be grossed-up for applicable federal, state and municipal
income, withholding, social security and other taxes on amounts paid you which
are not deductible by you on personal tax returns and will be made at the time
commissions become due as evidenced.

     3. STOCK OPTIONS.

     (a) Grant. Subject to and conditioned on the approval of' the Board of
Directors of QuatRx (the "Board"), acting in its capacity as committee under the
QuatRx 2000 Equity Incentive Plan, QuatRx shall grant to you options to purchase
up to 400,000 shares of the common stock of QuatRx at a price per share to be
determined by the Board in accordance with the Equity Incentive Plan (the
"Options"). The Options will be treated as incentive stock options under
applicable tax laws. The Options qualify for exemption under Rule 701 under the
Securities Act of 1933. The receipt and exercise of the Options shall be further
subject to you signing (following the Board's approval) and complying with the
terms, conditions, representations and warranties set forth in the QuatRx
Pharmaceuticals Company Stock Option Grant Agreement and the QuatRx
Pharmaceuticals Company Stock Option Grant Notice.

     (h) Vesting Schedule. Subject to and conditioned on the APPROVAL of the
Board, the Options will vest in accordance with the following schedule:

<TABLE>
<CAPTION>
Date                                Portion Vested
----                                --------------
<S>                                 <C>
November 1, 2004                    1/4 of the Options (100,000 shares)

For each full month of employment   l/48th of the Options (an additional
thereafter                          8,333.34 shares) for each such full month of
                                    employment (not to exceed 100% of the
                                    Options)
</TABLE>

     (c) The above vesting schedule will be subject to acceleration under
certain conditions specified in the Notice of Grant and related Stock Option
Agreement, including without limitation in connection with a Corporate
Transaction and in the event of termination of employment without Cause.

<PAGE>

     (d) You agree that upon your first exercise of the option and as a
condition to your purchase of shares thereunder, you will execute and deliver
(a) a Voting Agreement setting forth certain restrictions on and agreements
regarding the voting of the shares and (h) a Stock Restriction Agreement
imposing certain restrictions on your ability to transfer the shares you
purchase and imposing certain co-sale obligations on your transfer of shares,
each in a form substantially identical to the Second Amended and Restated Voting
Agreement and the Second Amended and Restated Stock Restriction Agreement signed
by the holders of Quatrx common stock dated as of May 15, 2003.

     4. SEVERANCE. Upon termination of your employment by the Company without
Cause (as defined in the Stock Option Agreement), you will be entitled to a
severance payment equal to 9 months' salary based on your then current salary
level, payable to you monthly by the fifth day of each calendar month for the
nine months following the month in which termination of your employment is
effective, subject to applicable withholding taxes.

     5. TAXES. Payments of amounts under this Agreement will be subject to
reduction by the amount of any applicable Federal, state, and municipal income,
withholding, social security and other taxes, state disability (workers'
compensation) insurance, and any other items which may be required or authorized
to be deducted by law. You will be solely responsible for filing any elections
under applicable tax laws (including, by way of example and not limitation,
elections under Section 83(b) of the Internal Revenue Code of 1986, as amended).

     6. At WILL EMPLOYMENT. There is no fixed or minimum term to your employment
by us. In consideration of your employment, you recognize that you are serving
solely at our will and that your employment can he terminated by us, with or
without cause, at any time, with or without notice from us. Your "at-will"
status cannot be modified without an express written agreement specifically
modifying such "at-will" status signed by both you and our President. You agree
that there is no continuing right to compensation.

     7. RESTRICTIONS ON DISCLOSURE OF INFORMATION. Concurrently with your
execution of this letter you will execute and deliver a Confidentiality,
Nondisclosure and Invention Assignment Agreement.

     8. MAINTENANCE OF RECORDS. Upon termination of your employment, you will
deliver to QuatRx all files and records of any nature which are in your
possession or control and which relate in any manner to your employment or to
the activities of QuatRx or any other entity that directly or indirectly
controls, is controlled by, or is under common control with QuatRx
("Affiliate"), without retaining any copies thereof', as well as all other
property of QuatRx and its Affiliates.

<PAGE>

Please execute a copy of this letter to indicate your agreement with the
foregoing,

                                        Very truly yours,

                                        QUATRX PHARMACEUTICALS COMPANY

                                        Robert L. Zerbe, Chief Executive Officer

Agreed:

/s/ Gary Onn
-------------------------------------
Mr. Gary Onn

Date: September 29, 2003

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}]]